Purpose, strategy and culture

View video on YouTube

Our strategy

We are a focused biopharma company. We prevent and treat disease with vaccines, specialty and general medicines. We focus on the science of the immune system and advanced technologies, investing in four core therapeutic areas (infectious diseases, HIV, respiratory/immunology and oncology). Our Ahead Together strategy means intervening early to prevent and change the course of disease, helping to protect people and support healthcare systems.

Explore more on our global website below.

Our R&D approach

Partner with GSK

Our portfolio

Learn about our product portfolio and how we’re prioritizing vaccines and specialty medicines to get ahead of disease together.

Our Products

How we help people thrive

At GSK, culture is something we all own. It’s powered by the little things GSK people do every day to help us get ahead of disease together. It drives delivery of our strategy and makes GSK a place where people can thrive. Being ambitious for patients, accountable for impact and making sure we always do the right thing is how we deliver for patients, shareholders, and of course the people who work here.

Our Code sets out the commitments GSK and our people make to get ahead together – so we can deliver on our ambition in the right way, bring our culture to life and make GSK an exciting and inspiring place to work.

Our US business areas

Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance. GSK is a company where outstanding people can thrive.

We prioritize innovation in vaccines and specialty medicines, maximizing the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics and advanced technologies, and our world-leading capabilities in vaccine and medicines development.

HIV

Fully dedicated to leaving no person living with HIV behind

Respiratory/ immunology

Continuously redefining treatment for COPD and asthma

Oncology

Purpose-built with a focus on acute and pressing needs in rare and women’s cancers

Specialty

Prioritizing R&D and commercial investment to improve patient outcomes

Vaccines

Protecting people from serious disease for well over 100 years

Our long-term priorities

We’re uniting science, technology and talent to make a difference in more people’s lives. We don’t just want to find new, better medicines and vaccines. By harnessing our science and technology, we have an opportunity to prevent disease in the first place, as well as change the course of a disease – helping to prevent or slow progression of an illness and limit long-term complications. Our broad portfolio and pipeline continues to strengthen, with key milestones across our core therapeutic areas in 2023. Strategic partnerships are critical to opening up new avenues of discovery. We have important collaborations, including with the University of Oxford on neurodegenerative diseases, Kings College London on cancer treatment and 23andMe on genetics and genomics.

Innovation

Vaccines and medicines in the pipeline
71
Assets in phase III/registration
18
Major approvals in 2023
4

We’re confident in our future. Our bold ambitions for patients are reflected in our upgraded growth outlooks to 2026 and 2031. This means more GSK vaccines and medicines, including innovative new products, will reach more people who need them than ever before.

Our performance

Creating value for patients, shareholders, society

Packs of medicinas and doses of vaccines delivered in 2023
2.3bn
Per share dividen in 2023 (£)
58p
Corporate income tax paid; in addition we paid duties, levies, transactional and employment taxes
£1.3bn

Being a responsible business is an integral part of our strategy. We have identified six ESG focus areas that address what is most material to our business and the issues that matter the most to our stakeholders: access to healthcare, global health and health security, environment, diversity, equity and inclusion (DEI), ethical standards, and product governance.

We recognize that being a responsible business is not a static requirement. This means that we will continue to evolve our approach in response to the rapidly changing operating environment and strive for continuous improvement to ensure we maintain strong ESG performance.

Responsibility

ESG Performance Report (PDF -2.0MB)